Clostridium difficile infection future or investigational therapies: Difference between revisions

	C. difficile Infection Microchapters
Home
Patient Information
Overview
Historical Perspective
Pathophysiology
Causes
Classification
Differentiating Clostridium difficile infectionfrom other Diseases
Epidemiology and Demographics
Risk Factors
Natural History, Complications and Prognosis
Diagnosis
History and Symptoms
Physical Examination
Laboratory Findings
Abdominal X Ray
Abdominal CT Scan
Other Imaging Findings
Biopsy
Treatment
Medical Therapy
Surgery
Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Clostridium difficile infection future or investigational therapies On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Clostridium difficile infection future or investigational therapies All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Clostridium difficile infection future or investigational therapies
CDC on Clostridium difficile infection future or investigational therapies
Clostridium difficile infection future or investigational therapies in the news
Blogs on Clostridium difficile infection future or investigational therapies
Directions to Hospitals Treating Clostridium difficile
Risk calculators and risk factors for Clostridium difficile infection future or investigational therapies

VisualWikitext

Latest revision as of 17:26, 18 September 2017

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Future or Investigational Therapies

References

Template:WikiDoc Sources

@@ Line 1: / Line 1: @@
 __NOTOC__
-{{Clostridium difficile}}
+{{Clostridium difficile infection}}
 {{CMG}}
 == Future or Investigational Therapies ==
-On December 14, 2005, researchers at McGill University in Montreal, Quebec, led by Dr. Ken Dewar and Dr. Andre Dascal and in collaboration with province-organized NPO Genome Quebec's research facility, announced they had cracked the genetic code of the highly virulent Quebec strain of ''C. difficile''. This was accomplished by using ultra high-throughput sequencing technology. The tests involved doing 400,000 DNA parallel sequencing reactions which took the bacterium's genome apart and reassembled it so it could be studied.<ref name=Loo_2005>{{cite journal |author=Loo V, Poirier L, Miller M, Oughton M, Libman M, Michaud S, Bourgault A, Nguyen T, Frenette C, Kelly M, Vibien A, Brassard P, Fenn S, Dewar K, Hudson T, Horn R, René P, Monczak Y, Dascal A |title=A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality |journal=N Engl J Med |volume=353 |issue=23 |pages=2442-9 |year=2005 |pmid=16322602}}</ref><ref>[http://www.iapm.ca/newsmanager/anmviewer.asp?a=144&z=14 Scientists map C. difficile strain] - Institute of Public Affairs, Montreal</ref>
-It is expected this will allow quicker detection of the disease and better treatment.
 ==References==
@@ Line 16: / Line 13: @@
 [[Category:Disease]]
 [[Category:Gastroenterology]]
-[[Category:Infectious disease]]
+[[Category:Bacterial diseases]]
 [[Category:Needs overview]]

Clostridium difficile infection future or investigational therapies: Difference between revisions

Latest revision as of 17:26, 18 September 2017

Future or Investigational Therapies

References

Navigation menu